Clinical Trials Browser

INDUSTRY × regorafenib × 30 days × Clear all

NCT06246643 2026-04-20

A Study of Continued Treatment With Regorafenib in Participants With Solid Tumors Who Have Participated in Other Bayer Studies

Phase 2 Active not recruiting

Solid Malignant Tumors

NCT04701476 2026-04-16

TATE and Pembrolizumab (MK3475) in mCRC and NSCLC

Phase 2 Recruiting

GastrointestinalThoracic

Lung Neoplasms, Colorectal Neoplasms